Norwegian patients and researchers at Akershus University Hospital and Oslo University Hospital have taken part in two large ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

The MarketWatch News Department was not involved in the creation of this content. -- Rybelsus(R) (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like semaglutide (the active ingredient in Ozempic and Wegovy). Media coverage of ...

Following a challenge brought by Novo Nordisk Inc., BBB National Programs’ National Advertising Division recommended Willow ...

Danish pharmaceutical company, Novo Nordisk, is set to introduce its diabetes drug, Ozempic, in India this December ...

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...

Rybelsus is a pill form version of semaglutide – an FDA approved prescribed medication to manage blood sugar levels in patients with type 2 diabetes. Another effect that Rybelsus has is that it can ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate.

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...